Two numbers will define what a low-income Medicare beneficiary pays for a covered prescription in 2027: up to $5.80 for a generic drug and up to $14.40 for a brand-name one. Those figures come from Extra Help, the federal subsidy that already eliminates the Part D premium and deductible for anyone who qualifies, replacing the percentage-based coinsurance most beneficiaries pay with a flat, capped copay instead. The bigger shift sits further down the bill: once a beneficiary’s total drug costs for the year reach $2,400, even that copay disappears.
A Flat Ceiling Instead of a Percentage
Extra Help works differently from the way most Part D coverage is priced. A beneficiary without the subsidy typically pays a deductible and then a coinsurance share, often 25 percent of a drug’s cost, until total spending clears a set threshold for the year. Extra Help replaces both of those steps for anyone who qualifies: there is no premium, no deductible, and no percentage-based coinsurance. In their place sits a single flat number that depends only on whether the drug filled is a generic or a brand-name product.
The contrast becomes sharper against the standard version of the benefit. A plan without Extra Help can charge a deductible as high as $700 in 2027, up from $615 in 2026, and its enrollees pay 25 percent coinsurance on covered drugs until their out-of-pocket spending reaches $2,100 in 2026 or $2,400 in 2027. An Extra Help recipient skips the deductible and the percentage math entirely, paying at most $5.80 or $14.40 per prescription depending on the drug’s category, regardless of how expensive that drug’s actual price tag is.
The subsidy’s flat-copay design is not new for 2027; it has applied in some form since Extra Help’s cost-sharing structure was overhauled earlier this decade, with the specific dollar ceilings adjusted most years to track drug-price inflation. What changes year to year is only the size of the ceiling, not the underlying promise that a qualifying beneficiary’s copay will never exceed a fixed, published amount no matter what a pharmacy charges for the drug itself.
Free download: IRMAA, the Medicare Savings Programs and Extra Help explained side by side, with the official form and contact for each. Get the free Medicare premium route finder.
The $2,400 Line That Empties the Bill
The $2,400 figure is not a separate Extra Help number; it is the same out-of-pocket threshold that governs everyone’s Part D coverage in 2027, generic-brand copay or not. Once total drug costs for the year cross that line, the plan moves into what Medicare calls catastrophic coverage, and covered drugs cost nothing for whoever is enrolled, whether they were paying a percentage of the price beforehand or a flat Extra Help copay.
That threshold counts more than what a beneficiary personally hands over at the pharmacy. Payments made on someone’s behalf, including the subsidy Extra Help itself provides, count toward the same running total that determines when the $2,400 line is crossed. In practice, that means a full-benefit Extra Help recipient filling a string of brand-name prescriptions can reach the threshold from the value of the drugs dispensed, not merely from the $14.40 copays that recipient is actually writing checks for, arriving at zero-cost coverage sooner than the raw copay numbers alone would suggest.
Qualifying for those numbers requires meeting income and resource limits that Social Security recalculates annually; for 2026, the income ceiling sits at $23,940 for an individual or $32,460 for a married couple, with resources capped at $18,090 and $36,100 respectively. Anyone who already qualifies for Medicaid, a Medicare Savings Program, or Supplemental Security Income is enrolled in Extra Help automatically, while everyone else has to file Social Security’s Application for Extra Help, known as form SSA-1020.
Who Has to Apply, and What Keeps the Subsidy Going
Social Security does not treat an Extra Help approval as permanent. The agency reviews most recipients’ eligibility roughly once a year, typically at the end of August, mailing a form that asks the beneficiary to confirm income and resources have not changed enough to affect the subsidy, a cycle that runs independently of the broader Medicare cost and coverage updates CMS releases each fall for the coming plan year. A recipient who returns the review form within 30 days keeps the same treatment through the following January; one who does not respond loses Extra Help entirely starting the next calendar year, reverting to a standard deductible and coinsurance structure without warning at the pharmacy counter.
A beneficiary who disagrees with a denial or a reduction has a formal appeal path rather than an informal one. Social Security first sends a pre-decisional notice explaining why the record shows someone ineligible, and the recipient has 10 days to supply corrected information before a final determination goes out. From there, a beneficiary has 60 days to file a formal appeal, which can proceed as a telephone hearing or a review of the paper file, with a right to bring a representative into the process.
None of that process changes the two figures a beneficiary actually sees at checkout. Whether someone qualifies through automatic enrollment in Medicaid or through a standalone application reviewed by Social Security, the 2027 result is identical: a copay that never exceeds $5.80 for a generic or $14.40 for a brand-name drug, and a total bill that reaches zero once drug costs for the year hit $2,400.
That combination turns Extra Help into something closer to a ceiling than a discount. A beneficiary managing several brand-name prescriptions could exhaust the $2,400 threshold within a matter of months given how much of a drug’s full price counts toward that total, leaving the remainder of the year with no drug costs at all rather than merely reduced ones. For a program aimed at people with the least financial cushion, the design front-loads the protection instead of spreading it thin across twelve months.
Tracking Prescription Costs Under Extra Help
Extra Help’s flat copay ceiling and the point at which it drops to zero both depend on totals that a beneficiary rarely tracks fill by fill, and the annual eligibility review that keeps the subsidy running arrives on its own separate calendar from everything else Medicare mails each fall. A beneficiary who misses that review, or who is not sure whether a given prescription is pushing them toward the point where covered drugs stop costing anything, has few tools built for watching both numbers at once.
The Medicare Cost & Coverage Protection Kit is a 10-page kit that lays out the new Part D out-of-pocket cap alongside a medication and cost tracker for logging what each fill counts toward it, plus the prior-authorization appeal steps for a plan that denies a covered drug.
See the current Part D out-of-pocket cap and the cost tracker in The Medicare Cost & Coverage Protection Kit.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
